Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre, Randomised, Double-blind, Placebo-controlled Trial to Determine the Effect of Dapagliflozin 10mg Once Daily on Cardiovascular Outcomes in Haemodialysis for Patients With End Stage Renal Disease (ESRD)

NCT04764097 is registered in ClinicalTrials.gov with Tan Tock Seng Hospital as lead sponsor.

NCT NCT04764097
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04764097 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre, Randomised, Double-blind, Placebo-controlled Trial to Determine the Effect of Dapagliflozin 10mg Once Daily on Cardiovascular Outcomes in Haemodialysis for Patients With End Stage Renal Disease (ESRD)
Lead sponsor
Tan Tock Seng Hospital
Phase
Phase 2/3
Overall status
Withdrawn
Start date
June 30, 2021
Completion date
June 30, 2026
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular diseases, end stage renal disease